Table 2.

A summary of the identified associations of Eph and ephrins with retinopathy of prematurity.

Name	Established Association with Retinopathy of Prematurity	Possible Mechanism	Possible Use in Clinical Practice	Reference
ephrinA4	Overexpression in the retina with Neovascularization Reduction in the number of neovascular tufts following intravitreal injection of an inhibitor (blocking ephrinA4)	Involvement in neovascularization	Potential therapeutic target	[59]
ephrinA5	Overexpression in the retina with neovascularization	Involvement in neovascularization	Potential therapeutic target	[60]
EphA2	Blocking EphA2 reduces pathological neovascularization without affecting the formation of normal retinal vessels.	EphA2 may be necessary for maximal induction of neovascularization by VEGF	Potential therapeutic target	[61]
ephrinB2 and EphB4	Reduction in the number of preretinal tufts following intravitreal injection of soluble forms of ephrinB2 and EphB4	Regulating the processes of retinal neovascularization	Potential therapeutic target	[62]
ephrinB2 and EphB4	Stimulation of EphB4 and ephrinB2 signaling enhanced hypoxia-induced angiogenesis	Regulating the processes of retinal neovascularization	Potential therapeutic targets	[64]